Private Plans Pay 84% Of Emergency Room Appendicitis Bills, Researchers Find

Private health plans are a lot more dominant in some parts of the health care market than others.

A major new paper and its supplements show private plans’ share of spending for 148 health conditions, for every year from 2010 through 2019, at the national, state and county levels.

For people under age 65, private plans accounted for a total of about 56% of the spending tracked, according to a team of researchers led by Joseph Dieleman of the Seattle-based Institute for Health Metrics and Evaluation.

In 2019, for people of all ages, private plans paid 84% of the $845 million hospital emergency rooms received for treating patients with appendicitis.

But private plans accounted for just 39% of the $52 million hospital emergency rooms received for checkups and other forms of “well person care.”

At doctors’ offices and clinics, private plans paid 73% of the appendicitis bills, 63% of the well-person care bills and 52% of the bills related to type 1 diabetes.

The paper appears behind a paywall on the website of the Journal of the Medical Association.

The authors want readers to use the paper to address questions such as why age-adjusted health care spending averages $13,332 per year in Nassau County, New York, and just $3,410 per year in Clark County, Idaho.

Employers and their benefits advisors could use the data to see how much more private payers are paying in a particular county than Medicare; identify procedures that are leading to huge out-of-pocket costs for private plan participants; find out where a procedure costs twice as much in one county as in a nearby county; and determine where private plans are the dominant spenders, and may have more negotiating clout, and where private plans are minor players and may have less ability to bargain for lower prices.

The data: The federal government now requires health insurers and some health care providers to post extensive cost data.

Turquoise, the Health Care Cost Institute and FAIR Health are examples of organizations that have created health care cost studies and tools based on the public data feeds, commercial claim databases or other sources.

Dieleman team says its paper draws on much bigger, broader, more detailed streams of data, including 40 billion insurance claims, with separate spending figures for Medicare plans, Medicaid plans and patients’ own pockets as well as private payers.

The spreadsheets that come with the paper break out spending totals, by year, location, type of provider and payer type, for everything from acute glomerulonephritis to well-person care.

 

Source Link

Recommended Articles

CMS Finalizes Major Changes To ACA Exchanges, Including Greater Access To Catastrophic Plans

Editor’s Note: Covered California is a State-Based Marketplace (SBM). For details on how these new rules will impact Covered California and other SBMs we recommend the following Princeton University linked report: (Broker rule changes appear at the bottom of the Princeton analysis.) https://shvs.org/wp-content/uploads/2025/06/SHVS_2025-Final-Marketplace-Integrity-Rule.pdf.   The Trump administration on Friday finalized a major rule reshaping the ...

Read More

Eroding ACA Enrollment Portends Higher Insurance Rates

Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s record enrollment. For ...

Read More

White House Adds Generic Drugs To Direct-To-Consumer TrumpRx Site

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx, in a bid to expand a platform that is key to his administration’s efforts to lower prescription drug costs in the U.S. The administration is adding more than 600 generic drugs to the site, President Donald Trump said at an event ...

Read More

Supreme Court Rejects Big Pharma Appeals Challenging Negotiated Drug Prices In Medicare

The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs. The court’s decision to deny ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square